Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Connect Biopharma Holdings (CNTB) Return on Sales (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Return on Sales for 2 consecutive years, with 866.88% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 85412.0% to 866.88% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 866.88% through Dec 2025, down 86627.0% year-over-year, with the annual reading at 866.88% for FY2025, 86627.0% down from the prior year.
  • Return on Sales hit 866.88% in Q4 2025 for Connect Biopharma Holdings, up from 1075.0% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.62% in Q2 2024 to a low of 1075.0% in Q3 2025.